Physician profile
Ingrid Cristian
NPI 1568624633
$37,699.47
in general payments reported to CMS, 2019-2025
15 companies · $20K in 2025
The $20K reported for 2025 was more than what 90% of Clinical Genetics (M.D.) providers received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,743 · 2020: $34.18 · 2022: $73.58 · 2023: $10K · 2024: $4,290 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Travel and Lodging: $5,172 · Consulting Fee: $4,000 · Food and Beverage: $2,355 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,200.00 |
| Travel and Lodging | $5,172.31 |
| Consulting Fee | $4,000.00 |
| Food and Beverage | $2,355.35 |
| Education | $121.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $34,246.32 | 2019-2025 | Palynziq, Voxzogo 1.2mg |
| Horizon Therapeutics Plc | $2,652.28 | 2019 | |
| Ptc Therapeutics, INC. | $270.92 | 2023-2025 | Emflaza, Sephience |
| Takeda Pharmaceuticals U.S.A., INC. | $121.80 | 2023-2025 | Vpriv, Elaprase |
| Amgen INC. | $99.20 | 2024-2025 | Ravicti |
| Acadia Pharmaceuticals INC | $61.90 | 2023 | Daybue |
| Genzyme Corporation | $37.26 | 2025 | |
| Cycle Pharmaceuticals INC | $33.90 | 2025 | Javygtor, Nityr |
| Travere Therapeutics, INC. | $32.45 | 2020-2023 | Cholbam |
| Alexion Pharmaceuticals, INC. | $30.60 | 2022 | |
| Intrabio INC | $27.64 | 2025 | Aqneursa |
| Springworks Therapeutics, INC. | $27.49 | 2025 | Gomekli |
| Genentech USA, INC. | $19.47 | 2023 | Evrysdi |
| Recordati_rare_diseases_inc. | $19.12 | 2022 | |
| Eusa Pharma (US) LLC | $19.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ingrid Cristian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.